¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Abnormal level of enzymes"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • electronic energy level
    ÀüÀÚ¿¡³ÊÁö¼öÁØ
  • fat blood level
    Áö¹æÇ÷Ãþ
  • firing level
    ¹ßÈ­¼öÁØ
  • ground water level
    ÁöÇϼö³ôÀÌ
  • level
    1. ¼öÁØ 2. Ãþ 3. Ä¡ 4. ³óµµ
  • level of significance
    À¯ÀǼöÁØ
  • maximal expiratory level
    Ãִ볯¼û¼öÁØ, ÃÖ´ëÈ£±â°ª
  • maximal inspiratory level
    ÃÖ´ëµé¼û¼öÁØ, ÃÖ´ëÈí±â°ª
  • maximum permissible level
    ÃÖ´ëÇã¿ë¼öÁØ
  • maximum safe intensity level
    ÃÖ´ë¾ÈÀü°­µµ¼öÁØ
  • noise level
    ¼ÒÀ½¼öÁØ, ÀâÀ½µµ
  • no-observed-effect level
    ¹«°üÂûÈ¿°ú¼öÁØ
  • peak level
    ÃÖ°íÄ¡
  • permissible radiation exposure level
    Çã¿ë¹æ»ç¼±ÇÇÆø¼±·®
  • saturation sound pressure level
    Æ÷È­¼Ò¸®¾Ð¼öÁØ, Æ÷È­À½¾Ð¼öÁØ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • background level
    ¹è°æ¼öÁØ
  • blood enzyme level
    Ç÷ÁßÈ¿¼Ò³óµµ
  • blood oxygenation level dependant contrast
    Ç÷Áß»ê¼ÒÄ¡ÀÇÁ¸´ëÁ¶µµ
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • effective perceived noise level
    ½ÇÈ¿°¨¼ö¼ÒÀ½¼öÁØ, ½ÇÁ¦°¨°¢¼ÒÀ½
  • electronic energy level
    ÀüÀÚ¿¡³ÊÁö¼öÁØ
  • fat blood level
    Áö¹æÇ÷Ãþ
  • firing level
    ¹ßÈ­¼öÁØ
  • ground water level
    ÁöÇϼö³ôÀÌ
  • level
    ¼öÁØ, Ãþ, Ä¡, ³óµµ
  • level
    Æ÷È­¼Ò¸®¾Ð¼öÁØ
  • level of significance
    À¯ÀǼöÁØ
  • maximal expiratory level
    Ãִ볯¼û¼öÁØ
  • maximal inspiratory level
    ÃÖ´ëµé¼û¼öÁØ
  • maximum permissible level
    ÃÖ´ëÇã¿ë¼öÁØ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • abnormal child
    ºñÁ¤»ó¾Æ(ÞªïáßÈä®).
  • abnormal echo
    ºñÁ¤»ó (ÞªïáßÈ) ¿¡ÄÚ, ºñÁ¤»ó (ÞªïáßÈ) ¸Þ¾Æ¸®
  • abnormal fusion
    ºñÁ¤»óÀ¶ÇÕ
  • abnormal growth
    ºñÁ¤»ó¼ºÀå
  • abnormal hemoglobin
    ÀÌ»óÇ÷»ö¼Ò(~Ì´Ë×ËÛ), ÀÌ»óÇì¸ð±Û·Îºó.
  • abnormal localization of immature precursor cells=ALIP
    ¹Ì¼º¼÷Àü±¸¼¼Æ÷ÀÇ ºñÁ¤»ó ±¹Àç
  • abnormal movements
    ÀÌ»ó¿îµ¿(ì¶ßÈê¡ÔÑ).
  • abnormal patency of the eustachian tube
    À̰ü°³¹æÁõ
  • abnormal position
    ºñÁ¤»óÀ§Ä¡
  • abnormal reflex
    ÀÌ»ó¹Ý»ç(~ÚãÞÒ).
  • abnormal retinal correspondance
    ÀÌ»ó¸Á¸·´ëÀÀ
  • abnormal shape
    ÀÌ»óÇüÅÂ
  • abnormal temperature
    ÀÌ»ó¿Âµµ, ÀÌ»óü¿Â(~ü¿Â).
  • abnormal uterine bleeding
    ÀÌ»óÀÚ±ÃÃâÇ÷(~í­Ïàõóúì).
  • abocclusion =abnormal occlusion
    °³±³(ËÒÎá).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • abnormal patency of the eustachian tube
    À̰ü°³¹æÁõ
  • abnormal position
    ºñÁ¤»óÀ§Ä¡
  • abnormal reflex
    ÀÌ»ó¹Ý»ç(~ÚãÞÒ).
  • abnormal retinal correspondance
    ÀÌ»ó¸Á¸·´ëÀÀ
  • abnormal shape
    ÀÌ»óÇüÅÂ
  • abnormal temperature
    ÀÌ»ó¿Âµµ, ÀÌ»óü¿Â(~ü¿Â).
  • abnormal uterine bleeding
    ÀÌ»óÀÚ±ÃÃâÇ÷(~í­Ïàõóúì).
  • abocclusion =abnormal occlusion
    °³±³(ËÒÎá).
  • hemoglobinopathy =abnormal hemoglobin disease
    Ç÷»ö¼Òº´Áõ.
  • subtotal abnormal shape
    ºÎºÐÀÌ»óÇüÅÂ
  • total abnormal shape
    ÀüüÀÌ»óÇüÅÂ
  • acceptable noise level
    Çã¿ë¼ÒÀ½
  • air fluid level
    °ø±â ¾×üÃþ
  • alertness level
    °æ°è±âÁØ(ÌíÌüÐññÞ).
  • antimicrobial level
    Ç×±ÕÁ¦Ä¡<¼öÁØ(â©ñÞ)>
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HCG, hCG Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó
  1. Placental Glycoprotein Hormone
&nbs...
CCL carcinoma cell line; certified cell line; Charcot-Leyden crystal; continuing care level; critical ca...
CL capillary lumen; cardiolipin; cell line; centralis lateralis; chemiluminescence; chest and left arm ...
SAL sensorineural activity level; sterility assurance level; suction-assisted lipectomy
SDL serum digoxin level; speech discrimination level
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HELLP Haemolysis, Elevated Liver Enzymes and Low Platelets
HELLP Hemolysis, Elevated Liver enzymes, and Low Platelet count
SBE Starch branching enzymes
TAM Transient abnormal myelopoiesis
UBCs Ubiquitin conjugating enzymes
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • R89.0
    Abnormal level of enzymes
    ÀÌ»ó È¿¼Ò ¼öÄ¡
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • subconscious level
    ÀáÀç ÀÇ½Ä ¼öÁØ
  • substrate level phosphorylation
    ±âÁú±Þ ÀλêÈ­
  • ultrastructural level
    Ãʹ̼¼ ±¸Á¶Àû ¼öÁØ
    ÀÎü¸¦ ±¸¼ºÇÏ´Â ÃÖ¼Ò ¹Ì¼¼ ÀÔÀÚÀÇ ¼öÁØ. ±¤ÇÐÇö¹Ì°æÀÇ ÇØ»ó·ÂÀ» ³ÑÀº ÃÊÇö¹Ì°æÀ̳ª ÀüÀÚÇö¹Ì°æÇÏ¿¡¼­ óÀ½À¸·Î º¸ÀÌ´Â ±¸Á¶.
  • abnormal behavior
    ÀÌ»ó Çൿ
    Á¤»óÀ» ¹þ¾î³­ Çൿ. ÇൿÀ¸·Î ³ªÅ¸³ª´Â °´°üÀûÀ¸·Î ÀÎÁ¤µÇ´Â ÀÌ»ó. ÀÌ»ó ÇൿÀº Á¤½Å Àå¾Ö¸¦ ¹Ý¿µÇÏ´Â °´°üÀû Áõ»óÀÌ µÇ´Â °ÍÀ¸·Î Á¤½Å ÀÇÇп¡¼­ÀÇ Áø´ÜÇлó, Çൿ °üÂûÀº Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇÑ´Ù. ÇൿÀº ÁÖ·Î »ç°í °úÁ¤À̳ª »ç°í ³»¿ë, °¨Á¤, Á¤¼­ ¹× ¿åµ¿ µîÀÌ ¹Ý¿µµÈ´Ù. °­¹Ú °ü³ä¿¡ ±âÀÎÇÏ´Â °­¹Ú ÇàÀ§, ¸Á»ó¿¡ ±âÀÎÇÏ´Â Çൿ ÀÌ»ó, ¿ïº´¼ºÀÇ Çൿ Áö¿¬, Á¶º´ÀÇ ÈïºÐ, ÇàÀ§ ½É¹Ú, ½Ä Çൿ ÀÌ»ó, ¼º Çൿ ÀÌ»ó, ¾Æµ¿ÀÇ Áö³ªÄ£ ¿òÁ÷ÀÓ µî, ´Ù¾çÇÑ ÀÌ»ó ÇൿÀÌ ÀÖ´Ù.
  • abnormal child
    ºñÁ¤»ó¾Æ
    Çüųª ±â´ÉÀûÀ¸·Î Á¤»óÀ» ¹þ¾î³­ ¾ÆÀÌ.
  • abnormal cusp
    ÀÌ»ó ±³µÎ, ºñÁ¤»ó ±³µÎ, ÀÌ»ó Ä¡¾Æ °áÀý
    µ¿ÀǾî=abnormal tubercle. ÀÌ»óÇÑ ÇüÅÂÀÇ Ä¡¾Æ °áÀý. Ä¡¾Æ¿¡ ÀÖ´Â ±³µÎÀÇ ¼ö³ª ÇüŰ¡ ºñÁ¤»óÀûÀÎ »óÅÂ.
  • abnormal eruption
    ºñÁ¤»ó ¸ÍÃâ
    À¯Ä¡³ª ¿µ±¸Ä¡¿¡ À־ Áö³ªÄ¡°Ô ºü¸£°Å³ª ´Ê°Ô ¸ÍÃâÇÏ´Â Çö»ó.
  • abnormal fetal presentation
    ÀÌ»ó ÅÂÀ§
    žÆÀÇ À§Ä¡°¡ ºñÁ¤»óÀûÀÎ °Í.
  • abnormal frenum
    ÀÌ»ó °è´ë, °è´ë ÀÌ»ó
    Á¤»óÀÌ ¾Æ´Ñ °è´ë, ¼Ò´ë. ¼Ò´ë°¡ Á¤»óº¸´Ù ª°Å³ª ±æ ¼ö ÀÖÀ¸¸ç, ±¸¼ø ¼Ò´ëÀÎ °æ¿ì¿¡´Â 1°³ ÀÌ»óÀÏ ¼öµµ ÀÖ´Ù.
  • abnormal fusion
    ºñÁ¤»ó À¶ÇÕ
    ¹ß»ý ½Ã Á¶Á÷ÀÌ Á¤»óÀûÀ¸·Î ÇÕÃÄÁöÁö ¸øÇÏ´Â »óÅÂ. ´ëºÎºÐ Á¤Áߺο¡ °á¼ÕÀ» ³ªÅ¸³½´Ù.
  • abnormal growth
    ºñÁ¤»ó ¼ºÀå
    ¼ºÀåÀÌ Á¤»óÀûÀÎ ¹üÀ§¸¦ ¹þ¾î³­ »óÅÂ. Á¤»óº¸´Ù »¡¸® ÀÚ¶ö ¼öµµ ÀÖ°í ´Ê°Ô ÀÚ¶ö ¼öµµ ÀÖ´Ù.
  • abnormal jaw closure
    ÀÌ»ó ¾Ç°ñ ±³ÇÕ, ¾Ç°ñ ±³ÇÕ ÀÌ»ó
    ¼Ò±¸Ä¡¿Í ´ë±¸Ä¡ÀÇ ±³ÇÕ¸éÀ̳ª ¹Ý´ëÆí ±³ÇÕ¸éÀÇ Á¢ÃËÀÌ Á¤»óÀ» ¹þ¾î³ª´Â °æ¿ì.
  • abnormal laterality syndrome
    ÁÂ¿ì ºñ´ëĪ ÀÌ»ó ÁõÈıº
    ½ÉÀå¿¡¼­ Á¤»óÀûÀÎ ÁÂ¿ì ´ëĪÀÌ µÚ¹Ù²î°Å³ª ºÒ¿ÏÀüÇÑ °æ¿ì·Î¼­, ÁÂÃøÀ̳ª ¿ìÃøÇüÀ¸·Î ´ëĪÀÎ °æ¿ì°¡ ÀÖ°í À̵鿡¼­ ¿©·¯ °¡Áö ½ÉÀå ±âÇüÀÌ µ¿¹ÝµÇ´Âµ¥ ÀÌ·¯ÇÑ °æ¿ì¸¦ ½ÉÀåÀÇ ÁÂ¿ì ºñ´ëĪ ÀÌ»ó ÁõÈıºÀ̶ó ÇÑ´Ù. À̵é Áúȯ¿¡¼­´Â ½ÉÀå »Ó ¾Æ´Ï¶ó ÁÖ ±â°üÁö¿Í »óÆóµ¿¸ÆÀÇ À§Ä¡ °ü°è ¹× ÆóÀÇ ºÐ¿±, °£°ú ºñÀåÀÇ ÇüÅ ¹× À§Ä¡°¡ ´Þ¶óÁö¸ç ƯÈ÷ ºñÀåÀÌ ¾ø´Â ¹«ºñÁõ
  • abnormal liquid
    ºñÁ¤»ó ¾×ü
  • abnormal movement
    ºñÁ¤»óÀû ¿îµ¿, ÀÌ»ó ¿îµ¿
    »óÇÏ¾Ç Ä¡¿­ ¹× ±³ÇÕÀÌ Á¤»óÀ» ¹þ¾î³ª ¾î±ß³­ »óÅ·ΠÇϾÇÀÌ ¿òÁ÷ÀÌ´Â °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
deaminating enzymes Enzymes catalyzing simple hydrolysis of C-NH2 bonds of purines, pyrimidines, and pterins, usually named in terms of the substrate, e.g., guanine deaminases, adenosine deaminases, AMP deaminases, pterin deaminases and thus producing ammonia; not generally used for deamination of noncyclic amides. Deaminases are distinguished from ammonia-lyases (EC group 4.3.1) in that the latter produce an unsaturation at the point of NH3 removal.
Synonym: deaminating enzymes.
(05 Mar 2000)
debranching enzymes Enzyme's that bring about destruction of branches in glycogen; formerly considered to be one enzyme, now known to be a mixture of transferases (4-alpha-d-glucanotransferase) and hydrolases (amylo-1,6-glucosidase).
Synonym: debranching factors.
(05 Mar 2000)
digestive enzymes Enzymes that are utilised in the digestive system, enzymes that are hydrolases of macromolecules (e.g., amylases, proteinases).
(05 Mar 2000)
DNA restriction enzymes <enzyme> Enzymes that are part of the restriction-modification systems. They catalyze the endonucleolytic cleavage of DNA sequences which lack the species-specific methylation pattern in the host cell's DNA. Cleavage yields random or specific double-stranded fragments with terminal 5'-phosphates. The function of restriction enzymes is to destroy any foreign DNA that invades the host cell. most have been studied in bacterial systems, but a few have been found in eukaryotic organisms. They are also used as tools for the systematic dissection and mapping of chromosomes, in the determination of base sequences of dnas, and have made it possible to splice and recombine genes from one organism into the genome of another.
Registry number: EC 3.1.21
(12 Dec 1998)
DNA restriction-modification enzymes Systems consisting of two enzymes, a modification methylase and a restriction endonuclease. They are closely related in their specificity and protect the DNA of a given bacterial species. The methylase adds methyl groups to adenine or cytosine residues in the same target sequence that constitutes the restriction enzyme binding site. The methylation renders the target site resistant to restriction, thereby protecting DNA against cleavage.
(12 Dec 1998)
transferring enzymes <enzyme> Transferases are enzymes transferring a group, for example, the methyl group or a glycosyl group, from one compound (generally regarded as donor) to another compound (generally regarded as acceptor). The classification is based on the scheme "donor:acceptor group transferase".
Registry number: EC 2.
(12 Dec 1998)
enzymes, coenzymes, and enzyme inhibitors Proteins or RNA that act as biological catalysts, their cofactors, and inhibitors.
(12 Dec 1998)
enzymes, immobilised Enzymes which are immobilised on or in a variety of water-soluble or water-insoluble matrices with little or no loss of their catalytic activity. Since they can be reused continuously, immobilised enzymes have found wide application in the industrial, medical and research fields.
(12 Dec 1998)
ACE level <investigation> This is a blood test which measures the concentration of angiotensin-converting enzyme (ACE) in the bloodstream.
Elevations in angiotensin-converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy.
The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels).
(15 Jan 1998)
acoustic reference level The biological reference level for sound measurements. When the term decibel is used to indicate the noise level, a reference quantity is implied; this reference value is usually expressed as a sound pressure of 20 micronewtons per square meter. The reference level is referred to as 0 decibels, the baseline of the scale of noise level's; this baseline is considered the weakest sound that can be heard by a person with very good hearing in an extremely quiet location. Other equivalent reference level's still being used include 0.0002 microbar and 0.0002 dyne per square centimeter.
(05 Mar 2000)
background level The average amount of a substance present in the environment. Originally referring to naturally occurring phenomena. Used in toxic substance monitoring.
(05 Dec 1998)
blood porphyrin level A test which is used to measure red blood cell porphyrin levels. Porphyrins are pigments found in both animal and plant life.
This test is useful in evaluating any number of porphyrin disorders (involving the various porphyrins) of red blood cells.
Increased levels of coproporphyrins can indicate congenital erythropoietic porphyria or sideroblastic anaemia.
Increased protoporphyrins may be seen in infection, thalassaemia, sideroblastic anaemia, iron deficient anaemia, increased erythropoiesis and lead poisoning. Increased uroporphyrins may indicate congenital erythropoietic porphyria or erythropoietic protoporphyria.
(27 Sep 1997)
carbon dioxide blood level A measure of the bicarbonate level in the blood based on a venipuncture specimen. The serum carbon dioxide is one of the normally reported values in the electrolytes profile. Lower levels of carbon dioxide indicate an acidosis. The normal level is 20 to 29 mEq/L. Lower than normal levels can indicate diabetic ketoacidosis, lactic acidosis, alcoholic ketoacidosis, kidney disease, renal failure, diarrhoea, Addison's disease, ethylene glycol poisoning or methanol poisoning. Greater than normal levels can be seen with excessive vomiting, hyperaldosteronism and Cushing's syndrome.
(27 Sep 1997)
vasopressin level This test measures the amount of ADH in the serum. It is used to detect disorders that may affect the level of ADH in the serum. Normal values are: 0 to 4.7 pg/ml. Elevated ADH levels can indicate a CNS infection, fluid imbalance, CNS tumour, SIADH or acute porphyria. Low levels can indicate: diabetes insipidus or damage to the pituitary gland.
(27 Sep 1997)
maximum permissible exposure level The highest level of exposure to a substance, usually noxious, in the environment or during diagnostic and therapeutic procedures, that a body can tolerate without injury.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • replacement level
    Àα¸ º¸Ãæ ¼öÁØ(ÃÑÀα¸¸¦ À¯ÁöÇÏ´Â µ¥¿¡ ÇÊ¿äÇÑ Ãâ»ý·ü)
  • resistance level
    (½Ã¼¼ÀÇ)ÀúÇ×¼±(½Ã¼¼°¡ ÁÁ±â ¶§¹®¿¡ ÆÇ¸Å°¡ Ȱ¹ßÇØÁ®,±× ÀÌ»óÀÇ ½Ã¼¼ »ó½ÂÀÌ µÐÇØÁö´Â °¡°Ý ¼öÁØ)
  • sea level
    ÇØ¸é
  • spirit level
    ÁÖÁ¤ ¼öÁرâ
  • water level
    ¼öÆò¸é
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á